524572
PHARMAID
Start SIP
Invest Now
Start SIP in PHARMAID
Performance
- Low
- ₹45
- High
- ₹48
- 52 Week Low
- ₹42
- 52 Week High
- ₹77
- Open Price₹47
- Previous Close₹47
- Volume2,349
- 50 DMA₹48.58
- 100 DMA₹51.21
- 200 DMA₹54.53
Investment Returns
- Over 1 Month -10.02%
- Over 3 Month -8.01%
- Over 6 Month -33.89%
- Over 1 Year -39.64%
Smart Investing Starts Here Start SIP with Pharmaids Pharmaceuticals for Steady Growth!
Pharmaids Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- -11.9
- PEG Ratio
- 1.2
- Market Cap Cr
- 159
- P/B Ratio
- 3.1
- Average True Range
- 2.98
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- -0.5
- RSI
- 40.19
- MFI
- 61.56
Pharmaids Pharmaceuticals Financials
Pharmaids Pharmaceuticals Technicals
EMA & SMA
Current Price
₹45.00
-1.56
(-3.35%)
- Bearish Moving Average 16
- Bullish Moving Average 0
- 20 Day
- ₹47.36
- 50 Day
- ₹48.58
- 100 Day
- ₹51.21
- 200 Day
- ₹54.53
Resistance and Support
45.8
- R3 50.50
- R2 49.20
- R1 47.10
- S1 43.70
- S2 42.40
- S3 40.30
Pharmaids Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2025-11-11 | Quarterly Results | |
| 2025-08-07 | Quarterly Results | |
| 2025-05-23 | Audited Results | |
| 2025-02-12 | Quarterly Results | |
| 2024-11-13 | Quarterly Results |
Pharmaids Pharmaceuticals F&O
About Pharmaids Pharmaceuticals
- NSE Symbol
- PHARMAID
- BSE Symbol
- 524572
- ISIN
- INE117D01018
Similar Stocks to Pharmaids Pharmaceuticals
Pharmaids Pharmaceuticals FAQs
Pharmaids Pharmaceuticals share price is ₹45 As on 20 January, 2026 | 21:39
The Market Cap of Pharmaids Pharmaceuticals is ₹158.7 Cr As on 20 January, 2026 | 21:39
The P/E ratio of Pharmaids Pharmaceuticals is -11.9 As on 20 January, 2026 | 21:39
The PB ratio of Pharmaids Pharmaceuticals is 3.1 As on 20 January, 2026 | 21:39
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.